NTT-LTD.
18.5.2023 14:01:25 CEST | Business Wire | Press release
NTT Ltd., a leading IT infrastructure and services company, and Cisco, a worldwide leader in technology, today announced a collaboration to develop and deploy joint solutions that empower organizations to improve operational efficiencies and advance sustainability goals.
Leveraging NTT’s Edge as a Service portfolio and Cisco’s IoT capabilities, solutions developed by the two companies will offer real-time data insights, enhanced security, improved decision-making, and reduced operational costs through predictive maintenance, asset tracking, and supply chain management capabilities.
The companies will deliver solutions that combine NTT’s Managed Services expertise, automation capabilities at the edge, and the management of complex IT environments, with Cisco’s IoT capabilities, including Low Power Wide Area Networking (LoRaWAN).
As part of today’s news, NTT has bolstered its IoT consulting and services business that brings together more than 1000 practitioners and 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories, utilities and more. NTT has already trained more than 500 Cisco sales experts to accelerate the companies’ combined capabilities and go-to-market efforts.
“We are accelerating our IoT business initiatives to deliver a powerful portfolio of repeatable services that can be tailored to meet customer demand for these kinds of solutions. We’re in a unique position,” said Devin Yaung, SVP of Group Enterprise IoT Products and Services at NTT.
“We are excited to work together to help transition our customers to this IoT-as-a-Service model so they can quickly realize the business benefits across industries and around the globe,” said Samuel Pasquier, VP of Product Management, Industrial IoT Networking, Cisco.
Transforming Water Management Through Smart Solutions
NTT and Cisco are developing solutions and go-to-market offers focusing on industries such as manufacturing, transportation, and healthcare, where there is a growing demand for edge computing and IoT solutions. The two companies are already deploying this advanced ‘ruggedized’ service to several customers including Compagnie Intercommunale Liégeoise des Eaux (CILE), a public water distribution company located in Belgium.
NTT and Cisco have deployed thousands of LoRaWAN sensors across CILE’s infrastructure to provide remote visibility that improves operational efficiencies related to water quality, consumption, distribution, and maintenance. The solution also includes advanced technologies such as smart distribution networks, remote reading through smart meters, smart grid for remote management, connected IoT objects, and AI, delivered as a managed service. The network also provides the building blocks to support other sustainability use cases such as waste management, parking management, water quality and street light controls.
“At CILE, we provide critical infrastructure for 24 cities in Belgium, which means efficiency, security and reliability are key," said William de Angelis, CIO and CDO at CILE. “With NTT and Cisco’s support, we have real-time insights into our facilities and distribution networks, including faster detection of leaks, allowing us to respond to issues instantaneously and expand the network to other sustainability use cases.”
NTT Ramps Up IoT Consulting and Services Business
In a move to prioritize and scale IoT for clients and partners, NTT has activated an IOT-dedicated business unit bringing together deep expertise and capabilities from around the globe. The team of 1,000 consultants, engineers, enterprise architects, and sustainability experts will build, deploy, and manage more than 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories and more.
“We’re doubling down on NTT’s IoT capabilities to meet customer demand,” continued Yaung. “What we’re doing is pulling together our collective knowledge and skillsets, and putting the full power of NTT behind it, to better service our customers and the increasing need to outfit or retrofit their organizations with the connectivity and visibility they need to improve day-to-day business operations.”
The global IoT market is expected to grow 19 percent in 2023, with a potential market size of $483 billion by 2027.
#ENDS#
About NTT Ltd.
As part of NTT DATA, a USD 30 billion IT services provider, NTT Ltd. is a leading IT infrastructure and services company serving 65% of the Fortune Global 500 and more than 75% of the Fortune Global 100. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments where networks, cloud and applications converge. We offer tailored infrastructure and ensure consistent best practices in design and operations across all of our secure, scalable and customizable data centers. On the journey towards a software-defined future, we support organizations with our platform-delivered infrastructure services. We enable a connected future.
Visit us at services.global.ntt
About Cisco
Cisco (NASDAQ: CSCO) is the worldwide leader in technology that powers the Internet. Cisco inspires new possibilities by reimagining your applications, securing your data, transforming your infrastructure, and empowering your teams for a global and inclusive future. Discover more on The Newsroom and follow us on Twitter at @Cisco.
Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005431/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom